These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 31544710)

  • 1. Targeting Ceramide Metabolism in Hepatocellular Carcinoma: New Points for Therapeutic Intervention.
    Grbčić P; Car EPM; Sedić M
    Curr Med Chem; 2020; 27(39):6611-6627. PubMed ID: 31544710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocarcinogenesis and ceramide/cholesterol metabolism.
    Morales A; Mari M; Garcia-Ruiz C; Colell A; Fernandez-Checa JC
    Anticancer Agents Med Chem; 2012 May; 12(4):364-75. PubMed ID: 22043999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceramide production mediates cinobufotalin-induced growth inhibition and apoptosis in cultured hepatocellular carcinoma cells.
    Cheng L; Chen YZ; Peng Y; Yi N; Gu XS; Jin Y; Bai XM
    Tumour Biol; 2015 Aug; 36(8):5763-71. PubMed ID: 25724183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoliposomal ceramide prevents in vivo growth of hepatocellular carcinoma.
    Tagaram HR; Divittore NA; Barth BM; Kaiser JM; Avella D; Kimchi ET; Jiang Y; Isom HC; Kester M; Staveley-O'Carroll KF
    Gut; 2011 May; 60(5):695-701. PubMed ID: 21193455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceramides promote apoptosis for virus-infected lymphoma cells through induction of ceramide synthases and viral lytic gene expression.
    Dai L; Trillo-Tinoco J; Bai A; Chen Y; Bielawski J; Del Valle L; Smith CD; Ochoa AC; Qin Z; Parsons C
    Oncotarget; 2015 Sep; 6(27):24246-60. PubMed ID: 26327294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C6 ceramide sensitizes the anti-hepatocellular carcinoma (HCC) activity by AZD-8055, a novel mTORC1/2 dual inhibitor.
    Liu M; Gu P; Guo W; Fan X
    Tumour Biol; 2016 Aug; 37(8):11039-48. PubMed ID: 26897748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual sphingosine kinase inhibitor SKI-II enhances sensitivity to 5-fluorouracil in hepatocellular carcinoma cells via suppression of osteopontin and FAK/IGF-1R signalling.
    Grbčić P; Tomljanović I; Klobučar M; Kraljević Pavelić S; Lučin K; Sedić M
    Biochem Biophys Res Commun; 2017 Jun; 487(4):782-788. PubMed ID: 28433634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altering the sphingosine-1-phosphate/ceramide balance: a promising approach for tumor therapy.
    Huwiler A; Pfeilschifter J
    Curr Pharm Des; 2006; 12(35):4625-35. PubMed ID: 17168766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical development of a C6-ceramide NanoLiposome, a novel sphingolipid therapeutic.
    Kester M; Bassler J; Fox TE; Carter CJ; Davidson JA; Parette MR
    Biol Chem; 2015 Jun; 396(6-7):737-47. PubMed ID: 25838296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of ceramide glucosylation sensitizes lung cancer cells to ABC294640, a first-in-class small molecule SphK2 inhibitor.
    Guan S; Liu YY; Yan T; Zhou J
    Biochem Biophys Res Commun; 2016 Aug; 476(4):230-236. PubMed ID: 27221045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum sphingolipidomic analyses reveal an upregulation of C16-ceramide and sphingosine-1-phosphate in hepatocellular carcinoma.
    Grammatikos G; Schoell N; Ferreirós N; Bon D; Herrmann E; Farnik H; Köberle V; Piiper A; Zeuzem S; Kronenberger B; Waidmann O; Pfeilschifter J
    Oncotarget; 2016 Apr; 7(14):18095-105. PubMed ID: 26933996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dysregulation of sphingolipid metabolic enzymes leads to high levels of sphingosine-1-phosphate and ceramide in human hepatocellular carcinoma.
    Miura K; Nagahashi M; Prasoon P; Hirose Y; Kobayashi T; Sakata J; Abe M; Sakimura K; Matsuda Y; Butash AL; Katsuta E; Takabe K; Wakai T
    Hepatol Res; 2021 May; 51(5):614-626. PubMed ID: 33586816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of lipids in pathophysiology, diagnosis and therapy of hepatocellular carcinoma.
    Buechler C; Aslanidis C
    Biochim Biophys Acta Mol Cell Biol Lipids; 2020 May; 1865(5):158658. PubMed ID: 32058031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
    Tong M; Che N; Zhou L; Luk ST; Kau PW; Chai S; Ngan ES; Lo CM; Man K; Ding J; Lee TK; Ma S
    J Hepatol; 2018 Oct; 69(4):826-839. PubMed ID: 29885413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C2-ceramide enhances sorafenib-induced caspase-dependent apoptosis via PI3K/AKT/mTOR and Erk signaling pathways in HCC cells.
    Jiang S; Wang Q; Feng M; Li J; Guan Z; An D; Dong M; Peng Y; Kuerban K; Ye L
    Appl Microbiol Biotechnol; 2017 Feb; 101(4):1535-1546. PubMed ID: 27807662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sphingolipid metabolic changes during chiral C2-ceramides induced apoptosis in human leukemia cells.
    Baek MY; Yoo HS; Nakaya K; Moon DC; Lee YM
    Arch Pharm Res; 2001 Apr; 24(2):144-9. PubMed ID: 11339634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Evaluation of Liposomal C8 Ceramide as a Potent anti-Hepatocellular Carcinoma Agent.
    Lv H; Zhang Z; Wu X; Wang Y; Li C; Gong W; Gui L; Wang X
    PLoS One; 2016; 11(1):e0145195. PubMed ID: 26727592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alkaline ceramidase 3 promotes growth of hepatocellular carcinoma cells via regulating S1P/S1PR2/PI3K/AKT signaling.
    Yin Y; Xu M; Gao J; Li M
    Pathol Res Pract; 2018 Sep; 214(9):1381-1387. PubMed ID: 30097213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceramide and polyunsaturated phospholipids are strongly reduced in human hepatocellular carcinoma.
    Krautbauer S; Meier EM; Rein-Fischboeck L; Pohl R; Weiss TS; Sigruener A; Aslanidis C; Liebisch G; Buechler C
    Biochim Biophys Acta; 2016 Nov; 1861(11):1767-1774. PubMed ID: 27570113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of sphingosine kinase 1 (SphK1) as a primary target of icaritin in hepatocellular carcinoma cells.
    Lu PH; Chen MB; Liu YY; Wu MH; Li WT; Wei MX; Liu CY; Qin SK
    Oncotarget; 2017 Apr; 8(14):22800-22810. PubMed ID: 28206952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.